StockData
IQVIA Holdings Inc. logo

IQVIA Holdings Inc. (IQV) KPIs and segments

IQVNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 9/3014% above fair value
$257.84+0.24 (+0.09%)

Close on Nov 18, 2026Market cap $42.49BP/E 31.3Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Iqvia · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Iqvia: 42 chỉ số vận hành, trong đó có R&D Solutions Contracted Backlog, Quarterly R&D Solutions Net New Bookings và Quarterly Contracted Net Book-to-Bill Ratio, lấy từ 176 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Research & Development Solutions($M)3
2,6392,5752,3971,8462,4272,3662,2572,1232,1622,1472,0952,151
Americas($M)
1,1931,1441,1288661,1121,1101,0179259691,0149861,175
Europe and Africa($M)
739722667399642601631605607557535556
Asia-Pacific($M)
707709602581673655609593586576574420
Commercial Solutions($M)3
1,7891,7931,7541,6731,6511,572
Americas($M)
894895856821825790
Europe and Africa($M)
678687688655640593
Asia-Pacific($M)
217211210197186189
Technology And Analytics Solutions($M)3
1,7891,7301,6311,6281,5461,6581,5541,4951,4531,531
Americas($M)
894927824830783859797783743823
Europe and Africa($M)
678758652646617640626569562550
Asia-Pacific($M)
21745155152146159131143148158
Contract Sales & Medical Solutions($M)3
210209188181177180172189186
Europe and Africa($M)
787560535354526054
Americas($M)
697068706972667376
Asia-Pacific($M)
636460585554545656
Americas($M)
2,0872,0391,9842,0701,9331,9351,8071,8531,8381,8631,8022,074
Europe and Africa($M)
1,4171,4091,3551,4231,2971,2411,2241,2981,2871,1781,1571,160
Asia-Pacific($M)
924920812871870841798807771773778634
Research & Development Solutions($M)
571526472402522473476478498493479524
Commercial Solutions($M)
410419381357379355
Technology And Analytics Solutions($M)
410504370389360421405361335404
Contract Sales & Medical Solutions($M)
12131211131291312
Remaining performance obligations (RPO)($M)
34,20036,40037,30034,40034,60034,90033,30032,80033,000
R&D Solutions Contracted Backlog($M)1
32,60034,20034,20032,70032,40032,10031,50031,10031,10030,60030,10029,700
Next 12 Months (NTM) Revenue Expected from Backlog($M)1
9,4009,2008,9008,3008,1008,1007,9007,9007,8007,8007,7007,500
Next 12 Months Backlog Conversion Growth (YoY)(%)
10.0%7.5%7.6%4.0%4.8%
Quarterly R&D Solutions Net New Bookings($M)
3,2003,1502,5002,6002,5002,1002,3002,7002,600
Quarterly Contracted Net Book-to-Bill Ratio(×)1
1.201.221.041.181.151.121.021.201.061.271.231.31
Trailing 12-Month (LTM) Contracted Net Book-to-Bill Ratio(×)
1.111.121.121.101.141.191.221.261.261.28
ASC 606 Remaining Performance Obligations (RPO)($M)
34,20036,40037,30034,20034,40034,60034,90033,50033,30032,80033,00031,700
Unearned Income (Contract Liabilities)($M)2
2,3132,2812,2612,1182,1602,1231,9401,7791,8241,8111,9141,799
Unbilled Services (Contract Assets & Unbilled Receivables)($M)1
1,7411,7691,7631,7831,8911,8961,8961,8562,0611,9382,0191,942
Unbilled Receivables Share of Unbilled Services(%)
73.0%75.0%73.0%71.0%68.0%68.0%69.0%69.0%67.0%69.0%67.0%68.0%
Net Contract Balance (Unbilled Services Less Unearned Income)($M)
-572-512-498-335-269-227-4477237127105143
Consolidated Revenue Growth — Reported (YoY)(%)1
8.0%8.7%8.4%10.3%5.2%5.3%2.5%2.3%4.3%2.3%2.3%3.5%
Consolidated Revenue Growth — Constant Currency (YoY)(%)
8.6%8.5%6.0%8.1%3.9%3.6%3.5%3.0%4.2%3.5%2.9%2.6%
Research & Development Solutions — Segment Revenue($M)4
2,6392,5752,3971,8462,4272,3662,2572,1232,1622,1472,0952,151
R&D Solutions Revenue Growth — Reported (YoY)(%)
8.7%8.8%6.2%9.9%4.5%2.5%-0.3%-1.3%-1.9%-2.4%3.4%4.5%
R&D Solutions Revenue Growth — Constant Currency (YoY)(%)
9.1%8.6%4.2%8.2%3.4%1.3%1.1%1.0%2.0%3.3%3.8%3.7%
R&D Solutions — Cost of Revenues (Exclusive of D&A, ASU 2023-07)($M)
1,8111,8011,6751,2591,6621,6521,5511,4301,4421,4311,3951,416
R&D Solutions — Selling, General & Administrative Expenses (ASU 2023-07)($M)
257248250185243241230215222223221211
Commercial Solutions — Segment Revenue (Recast Effective Q1 2026)($M)4
1,7891,7931,7541,6731,6511,572
Commercial Solutions Revenue Growth — Reported (YoY)(%)
6.9%8.6%11.6%
Commercial Solutions Revenue Growth — Constant Currency (YoY)(%)
7.9%8.4%8.5%
Commercial Solutions — Cost of Revenues (Exclusive of D&A, ASU 2023-07)($M)
1,1191,1321,1211,0651,042980
Commercial Solutions — Selling, General & Administrative Expenses (ASU 2023-07)($M)
260242252251230237
Technology & Analytics Solutions — Segment Revenue (Legacy through FY2025)($M)4
1,7301,6311,6281,5461,6581,5541,4951,4531,531
TAS Revenue Growth — Reported (YoY, Legacy through Q4 2025)(%)
9.8%5.0%8.9%-6.4%-8.3%-8.6%-2.7%0.6%2.1%
TAS Revenue Growth — Constant Currency (YoY, Legacy through Q4 2025)(%)
7.1%3.3%6.8%7.6%9.5%8.2%3.8%1.0%1.3%
TAS — Cost of Revenues (Exclusive of D&A, Legacy through FY2025)($M)
9891,0141,0099491,001922909889903
TAS — Selling, General & Administrative Expenses (Legacy through FY2025)($M)
237247230237236227225229224
Contract Sales & Medical Solutions — Segment Revenue (Legacy through FY2025)($M)4
210209188181177180172189186
CSMS Revenue Growth — Reported (YoY, Legacy through Q4 2025)(%)
18.6%16.1%9.3%-4.2%-4.8%-1.6%-2.3%3.8%2.2%
CSMS Revenue Growth — Constant Currency (YoY, Legacy through Q4 2025)(%)
15.3%13.9%6.4%2.1%3.2%1.1%2.8%7.1%1.7%
CSMS — Cost of Revenues (Exclusive of D&A, Legacy through FY2025)($M)
181181162156149154148160159
CSMS — Selling, General & Administrative Expenses (Legacy through FY2025)($M)
171514141514151615
Total Segment Profit($M)2
981945853954879852831912915863827
Unallocated Corporate & Shared Service Expenses($M)
52840-14203841-13594642106
Total Segment Selling, General & Administrative Expenses($M)
517490502482494471467466463463466
Americas — Consolidated Revenue($M)
2,0872,0391,9842,0701,9331,9351,8071,8531,8381,8631,8022,074
Total Global Employees
95,00094,00093,00091,00090,00089,00088,00088,00087,000
Adjusted EBITDA($M)4
1,0329949321,046949910883996939887862966
Trailing 12-Month (LTM) Adjusted EBITDA($M)
4,0043,9213,8373,7883,7383,7283,7053,6843,6543,6033,5803,569
Restructuring & Related Expenses (Adjusted EBITDA Add-Back)($M)
41675333304242738392224
Acquisition-Related Expenses (Adjusted EBITDA Add-Back)($M)
81011115888710473
Stock-Based Compensation Expense (Adjusted EBITDA Add-Back)($M)
839565605560724854485645
Adjusted Net Income($M)6
557527492588515486479564523487468523
Adjusted Pre-Tax Income($M)
683648599715625593589689643600572640
Adjusted Tax Expense($M)
124119106127109107110125120113
Purchase Accounting Amortization (Pre-Tax Reconciliation Add-Back)($M)
163136137149138131125138139133129149
Adjusted Diluted Earnings per Share($)
3.343.152.903.4232.812.703.122.842.642.542.84
Adjusted Basic Earnings per Share($)
3.383.172.923.463.032.832.733.152.872.672.572.88
Non-GAAP Free Cash Flow (Form 8-K)($M)
667360491561772292426721571445377568
Net Debt (Form 8-K Leverage Table)($M)3
13,81814,09013,88613,74413,14313,45112,59012,28111,94011,71312,09212,297
Gross Debt (Form 8-K Leverage Table)($M)
16,06715,99915,83315,72414,95715,49014,33013,98313,51213,25813,53613,673
Gross Leverage Ratio (Gross Debt / LTM Adjusted EBITDA)(×)
4.014.084.134.154.004.163.873.803.703.683.783.83
Net Leverage Ratio (Net Debt / LTM Adjusted EBITDA)(×)
3.453.593.623.633.523.613.403.333.273.253.383.45
Remaining Share Repurchase Authorization($M)
2,8192,8191,2171,9811,9812,5882,1632,3632,363
Goodwill — Research & Development Solutions($M)3
3,8193,6913,6223,6293,0322,7162,6152,6082,6252,4312,4332,439
Goodwill — Commercial Solutions (Recast Post-Q1 2026)($M)
13,08112,91312,92212,987
Goodwill — Technology & Analytics Solutions (Legacy through FY2025)($M)
13,42412,74812,74612,26511,95712,31411,90011,93511,976
Goodwill — Contract Sales & Medical Solutions (Legacy through FY2025)($M)
167168149147145152146148152
Severance & Employee Termination Restructuring Reserve($M)
616743313334282146423436
Peer Benchmark: ICON plc (ICLR) — Remaining Performance Obligations / Backlog($M)11
16,40015,70015,00014,90014,00014,40015,50015,90015,50015,80015,30014,800
ICON plc (ICLR) — Consolidated Revenue($M)
2,0252,0632,0342,0842,0392,0152,0422,0422,043
ICON plc (ICLR) — Operating Income($M)
199138174-223231227303157242
Medpace Holdings (MEDP) — Remaining Performance Obligations($M)
3,8003,5003,5003,6003,5003,5003,4003,5003,5003,2003,2002,900
Medpace Holdings (MEDP) — Consolidated Revenue($M)
716707707660603559533528511
Medpace Holdings (MEDP) — Operating Income($M)
166147142142126114112105104
Charles River Laboratories (CRL) — Remaining Performance Obligations($M)
675700702667649727782788804857920986
Charles River Laboratories (CRL) — Consolidated Revenue($M)
9831,0049961,0051,0329841,0101,0261,012
Charles River Laboratories (CRL) — Operating Income($M)
20312012013410075117152126
Fortrea Holdings (FTRE) — Remaining Performance Obligations($M)
4,3914,4424,6164,6324,5484,4754,4924,4304,4914,3574,3024,763
Fortrea Holdings (FTRE) — Consolidated Revenue($M)
692678636701710651675662662
Fortrea Holdings (FTRE) — Operating Income($M)
1515-3-9-330-520-18-51-37
U.S. Payrolls: Management, Scientific & Technical Consulting (BLS NAICS 5416)10
1,888,4001,887,9001,875,2001,871,6001,860,0001,858,7001,864,3001,880,0001,857,3001,861,7001,856,0001,864,300
U.S. Payrolls: Computer Systems Design & Related Services (BLS NAICS 5415)
2,350,9002,368,3002,369,6002,380,6002,387,6002,399,9002,408,9002,431,4002,437,6002,444,7002,439,8002,449,800
U.S. Payrolls: Professional & Technical Services (BLS NAICS 54)
10,848,40010,833,60010,795,60010,784,60010,760,60010,768,00010,782,30010,813,90010,795,00010,820,60010,790,10010,800,100
U.S. Average Hourly Earnings: Professional & Business Services ($/hr)($)
46.1045.6345.2844.9644.7444.2143.6743.3142.7042.1941.6841.18
U.S. PPI: Pharmaceutical Preparation Manufacturing (BLS NAICS 325412, Index)(×)
929.25926.18926.04919.30918.73914.85916.46918.46918.07913.98908.96896.41
U.S. PPI: In-Vitro Diagnostic Substance Manufacturing (BLS NAICS 325413, Index)(×)
300.64300.62303.92300.52299.75297.66291.67284.50284.44284.62284.52284.15
U.S. PPI: Management Consulting Services (BLS Index)(×)
127.25136.26137.72130.44134.56135.96136.51134.88134.38137.89132.66132.96
U.S. PPI: Computing Infrastructure, Data Processing & Hosting (BLS Index)(×)
127.44124.04123.04123.64123.94123.66121.88119.35119.62119.64119.25119.03
USD / EUR Monthly Spot Exchange Rate (Federal Reserve H.10)(×)
1.151.151.161.171.171.151.081.051.111.081.091.09
USD / GBP Monthly Spot Exchange Rate (Federal Reserve H.10)(×)
1.341.331.331.341.351.361.291.261.321.271.271.27
JPY / USD Monthly Spot Exchange Rate (Federal Reserve H.10)(×)
156.42160.77158.68155.91147.86144.48149.06153.81142.95157.86149.82143.98
Consolidated Revenue (GAAP)($M)10
4,4284,3684,1514,3644,1004,0173,8293,9583,8963,8143,7373,868
Cost of Revenue (Exclusive of D&A)($M)
2,9302,9332,7962,9282,7272,6942,5312,5802,5182,4882,4442,478
Selling, General & Administrative Expenses($M)
569574502468514509508453522509508556
Restructuring Costs($M)
36635124203229-428281517
Operating Income (GAAP)($M)
572506514627553506496626550520506501
Interest Expense($M)
203197192193189182165171170163166181
Income Before Income Taxes($M)
386301328537408323323544349436340373
Income Tax Expense($M)
76605959765661112657549-102
Net Income Attributable to IQVIA (GAAP)($M)
350256274514331266249437285363288469
Diluted Earnings per Share (GAAP)($)
2.101.531.611.931.541.401.551.971.56
Weighted Average Diluted Shares(M)
167167170172173177184184184
Total Assets($M)8
30,47429,88129,67529,94428,72728,63227,32226,89927,18026,39826,57426,681
Cash and Cash Equivalents($M)
2,2491,9091,9471,9801,8142,0391,7401,7021,5721,5451,4441,376
Accounts Receivable and Unbilled Services, Net($M)
3,2933,3453,3463,4003,2693,3443,2683,2043,1963,2553,4263,381
Unearned Income (Current Deferred Revenue)($M)
2,3132,2812,2612,1182,1602,1231,9401,7791,8241,8111,9141,799
Property, Equipment and Software, Net($M)
534547516533525536533535513503513523
Goodwill($M)
16,90016,60416,54416,61615,94815,61115,02714,71015,09114,47714,51614,567
Other Identifiable Intangible Assets, Net($M)
4,7384,7494,8034,9624,7074,5964,5034,4994,7344,6084,7254,839
Total Liabilities($M)
23,68323,58023,32623,31422,43922,84621,33720,83220,21319,68420,23020,569
Stockholders' Equity($M)
6,6606,1716,2216,5036,1605,7785,9776,0676,9676,7146,3446,112
Operating Cash Flow (GAAP)($M)5
825558618735908443568885721588522747
Capital Expenditures (Additions to Property, Equipment & Software)($M)
158198127174136151142164150143145179
Depreciation and Amortization($M)
321292288317286276265303278269264316
Stock-Based Compensation (Cash Flow)($M)
839565605560724854485645
Business Acquisitions, Net of Cash Acquired($M)
3891633791648318113486428791427
Repurchases of Common Stock (Cash Flow)($M)
039855221206573751,15020000229

16 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Latest reported company period: Q3 2026 (ended September 30, 2026; Form 8-K filed October 27, 2026 and Form 10-Q filed October 29, 2026) and full fiscal year FY2025 (ended December 31, 2025; Form 10-K filed February 18, 2026).
  • Primary operational metrics for IQVIA's clinical research and healthcare intelligence business are R&D Solutions Contracted Backlog ($32.6B at Q3 2026 following a $2.1B adjustment for trials inactive >18 months), Next-12-Month Expected Backlog Revenue Conversion ($9.4B at Q3 2026, +10.0% YoY), Quarterly & LTM Net New Bookings ($3.2B in Q3 2026; $11.7B LTM, +14% YoY), Quarterly & LTM Contracted Net Book-to-Bill Ratio (1.20x in Q3 2026), and ASC 606 Remaining Performance Obligations ($34.2B at Q3 2026).
  • Segment Reorganization (Effective Q1 2026): IQVIA combined its former Technology & Analytics Solutions (TAS) and Contract Sales & Medical Solutions (CSMS) segments into a single Commercial Solutions segment alongside Research & Development Solutions (R&DS). Both the recast Commercial Solutions series (Q1 2025 – Q3 2026) and the legacy TAS and CSMS series (through Q4 2025 / FY2025) are presented, including segment Cost of Revenues and segment SG&A disclosed under ASU 2023-07.
  • Standalone vs. Consolidated Assessment: IQVIA Holdings Inc. files only U.S. GAAP consolidated financial statements with the SEC and omits parent-only Schedule I under Regulation S-X Rule 5-04 because restricted net assets of subsidiaries do not exceed 25% of consolidated net assets; therefore, consolidated-minus-standalone parent subtraction is not applicable. Instead, 6 years (FY2020–FY2025) of audited UK statutory accounts (FRS 101, in £ thousands) for IQVIA Ltd. (UK Companies House #03022416, £3.04B FY2025 turnover, 3,894 employees) are presented in a dedicated group.
  • All figures are strictly as reported (with verbatim source quotes attached to text-extracted values; inequality-bounded marketing claims are excluded). The only arithmetic applied is cumulative period splitting (Q4 = full year − nine months; quarterly = year-to-date − prior year-to-date), marked with its formula.

Không hiện vì thiếu các kỳ gần đây (18)

  • R&D Solutions — Clinical Backlog, Net New Bookings & Book-to-Bill › Quarterly R&D Solutions Net New Bookings › Trailing 12-Month (LTM) R&D Solutions Net New Bookings
  • UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Global Scope 1 Direct GHG Emissions (tCO2e)
  • UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Global Scope 2 Location-Based GHG Emissions (tCO2e)
  • UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Global Scope 2 Market-Based GHG Emissions (tCO2e)
  • UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Global Scope 3 Value-Chain GHG Emissions (tCO2e)
  • UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Global Scope 1 & 2 Energy Consumption (MWh)
  • UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Women Share of Global Workforce
  • UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e) › Women Share of Global People Managers
  • UK Statutory Gender Pay Gap Disclosures across Operating Entities › Global Total Market-Based GHG Emissions (Scope 1, 2 & 3, tCO2e)
  • Consolidated Financial Statement Context (GAAP Reference) › Consolidated Revenue (GAAP) › Gross Profit
  • Non-Identified Patient Records ('more than 1.2 billion comprehensive, longitudinal, non-identified patient records' in Form 10-K Item 1) — inequality-bounded figure ('more than').
  • Total Countries of Operation ('operations in more than 100 countries' in Form 10-K Item 1) — inequality-bounded figure; exact physical office country count (~80–82 countries in Item 2) is included instead.
  • Technology & Analytics Solutions Headcount ('over 25,000 technology, analytics, and consulting professionals' in Form 10-K Item 1) — inequality-bounded figure in recent Form 10-Ks.
  • Clinical Trial Sites & Investigators ('more than 50,000 clinical trial sites' in ESG/IR narratives) — inequality-bounded marketing figure.
  • Q4 2024 and Q4 2025 Quarterly R&D Solutions Net New Bookings ('over $2.5 billion' and 'over $2.7 billion' in Form 8-K) — inequality-bounded text figures excluded from the quarterly bookings series.
  • Organic Revenue Growth Rates on Earnings Calls (e.g., Q3 2026 ~6% consolidated organic growth, ~7% R&DS, ~4% Commercial Solutions) — disclosed intermittently in earnings call remarks without a continuous 3-quarter table in Form 8-K/10-Q.
  • Emerging Biopharma (EBP) Share of R&DS Backlog / RFP Dollars (~10% pre-commercial EBP share in Q1–Q2 2022 calls; $33B EBP industry funding in Q4 2025 call) — one-off qualitative call commentary without a continuous series.
  • Global Environmental GHG Inventory (Scope 1, 2 & 3 tCO2e and Energy Consumption MWh) & Global Workforce Gender Percentages — latest published IQVIA Sustainability Report covers FY2019–FY2024 only (FY2025 global environmental inventory not yet released; audited 5-year FY2021–FY2025 UK SECR energy & carbon series for IQVIA Ltd. is presented in Group 6).

Dữ liệu cập nhật 2026-11-08.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Iqvia

See a number that looks wrong?